Liu Bo, Shi Tiantian, Tian Shaojiang, Luo Xianrui, Yang Chen, Wen Jing
Department of Nephrology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Department of Blood Purification Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Evid Based Complement Alternat Med. 2022 Jun 25;2022:9192655. doi: 10.1155/2022/9192655. eCollection 2022.
For investigating the efficacy and mechanism of Roxadustat + oral iron in the treatment of elderly chronic kidney disease (CKD) complicated with anemia.
A total of 100 elderly patients with CKD and anemia admitted to our hospital between April 2020 and December 2021 were enrolled as research subjects, and the patients were assigned to control group (Con group, = 50) or experimental group (Exp group, = 50). The patients in the Con group were given oral iron, and those in the Exp group were given Roxadustat capsule based on the Con group. Both groups were given subcutaneous injection of recombinant human erythropoietin. The clinical efficacy, anemia indexes, iron metabolism indexes, inflammatory indexes, and adverse reactions were compared between the two groups.
The Exp group showed a notably higher treatment effective rate than the Con group ( < 0.05). After treatment, the anemia indexes, iron metabolism indexes, and inflammatory indexes in the Exp group were notably better than those in the Con group ( < 0.05). The Exp group showed a notably lower incidence of adverse reactions during treatment than the Con group ( < 0.05).
Roxadustat plus oral iron yields a pronounced clinical efficacy in the therapy of elderly patients with CKD and anemia.
探讨罗沙司他联合口服铁剂治疗老年慢性肾脏病（CKD）合并贫血的疗效及机制。
选取2020年4月至2021年12月我院收治的100例老年CKD合并贫血患者作为研究对象，将患者分为对照组（Con组，n = 50）和实验组（Exp组，n = 50）。Con组患者给予口服铁剂，Exp组患者在Con组基础上给予罗沙司他胶囊。两组均皮下注射重组人促红细胞生成素。比较两组的临床疗效、贫血指标、铁代谢指标、炎症指标及不良反应。
Exp组治疗有效率显著高于Con组（P < 0.05）。治疗后，Exp组的贫血指标、铁代谢指标及炎症指标明显优于Con组（P < 0.05）。Exp组治疗期间不良反应发生率显著低于Con组（P < 0.05）。
罗沙司他联合口服铁剂治疗老年CKD合并贫血患者具有显著的临床疗效。
